🎤 Upcoming Biotech Conferences
Loading conferences...
Free public preview
Track cancer catalysts with approval-probability scores and free alerts.
Oncology Biotech Pipeline: Cancer Drugs in Clinical Development
Every cancer program BioRadar tracks across 35 public biotech companies — drug candidates, trial phases and upcoming FDA decisions. Updated automatically.
BioRadar is tracking 819 cancer drug programs across 35 public companies, with 2 upcoming FDA decisions in this area. The most active companies by program count are IBRX, GILD, LLY, SNDX, JAZZ.
819Drug programs
35Companies
165In Phase 3
2Upcoming FDA dates
Upcoming FDA decisions in Oncology (Cancer)
Companies with cancer programs
IBRX
119 programs
GILD
104 programs
LLY
88 programs
SNDX
81 programs
JAZZ
60 programs
SMMT
39 programs
ADCT
38 programs
ACHV
24 programs
INBX
22 programs
CELC
21 programs
ARVN
19 programs
CORT
18 programs
ORIC
18 programs
INO
17 programs
ZYME
17 programs
AIM
15 programs
CMPS
14 programs
COGT
14 programs
CADL
12 programs
VERU
11 programs
SLS
10 programs
NUVL
9 programs
ARTV
8 programs
MAIA
7 programs
AGIO
6 programs
BHVN
5 programs
BTAI
5 programs
ACRV
3 programs
APGE
3 programs
GLUE
3 programs
TLSA
3 programs
CYTK
2 programs
SRRK
2 programs
ARWR
1 program
IONS
1 program
Phase 3 oncology (cancer) programs (165)
| Ticker | Drug | Indication |
|---|---|---|
| ACHV | Docetaxel | Castrate-Resistant Prostate Cancer |
| ACHV | Custirsen | Non-Small Cell Lung Cancer |
| ACHV | Prednisone | Prostate Cancer |
| ACHV | Dexamethasone | Prostate Cancer |
| ACHV | cabazitaxel | Prostate Cancer |
| ACHV | custirsen sodium | Prostate Cancer |
| ACHV | isotonic, 0.9% sodium chloride | Castrate-Resistant Prostate Cancer |
| ACHV | TOCOSOL Paclitaxel | Breast Neoplasm |
| ACHV | Taxol | Breast Neoplasm |
| ADCT | Rituximab | Relapsed Diffuse Large B-Cell Lymphoma |
| ADCT | Gemcitabine | Relapsed Diffuse Large B-Cell Lymphoma |
| ADCT | Oxaliplatin | Relapsed Diffuse Large B-Cell Lymphoma |
| ARVN | ARV-471 | Advanced Breast Cancer |
| ARVN | Fulvestrant | Advanced Breast Cancer |
| ARVN | Letrozole | Breast Cancer |
| ARVN | Vepdegestrant (ARV-471/PF-07850327) | Breast Cancer |
| CADL | Pembrolizumab | Non-squamous, Non-Small Cell Lung Cancer |
| CADL | Docetaxel | Non-squamous, Non-Small Cell Lung Cancer |
| CELC | Gedatolisib | Breast Cancer |
| CELC | Arm C: Gedatolisib + Palbociclib + Letro | Breast Cancer |
| CELC | Arm B: Ribociclib + Fulvestrant | Breast Cancer |
| CELC | Arm A: Gedatolisib + Palbociclib + Fulve | Breast Cancer |
| CELC | Arm D: Ribociclib + Letrozole | Breast Cancer |
| CELC | Palbociclib | Breast Cancer |
| CELC | Alpelisib | Breast Cancer |
| COGT | Sunitinib | Advanced Gastrointestinal Stromal Tumors |
| COGT | CGT9486 | Advanced Gastrointestinal Stromal Tumors |
| COGT | Midazolam | Advanced Gastrointestinal Stromal Tumors |
| CORT | Relacorilant 150 mg once daily (QD) | Ovarian Neoplasm |
| CORT | Nab-paclitaxel 100 mg/m^2 | Ovarian Neoplasm |
| CORT | Nab-paclitaxel 80 mg/m^2 | Ovarian Neoplasm |
| CORT | Nab-paclitaxel | Metastatic Pancreatic Ductal Adenocarcinoma |
| CORT | Relacorilant, 100 mg and 25 mg | Metastatic Pancreatic Ductal Adenocarcinoma |
| GILD | Cyclophosphamide | Relapsed or Refractory Large B-cell Lymphoma |
| GILD | KITE-753 | Relapsed or Refractory Large B-cell Lymphoma |
| GILD | Fludarabine | Relapsed or Refractory Large B-cell Lymphoma |
| GILD | Zimberelimab | Advanced Upper Gastrointestinal Tract Adenocarcino |
| GILD | Domvanalimab | Advanced Upper Gastrointestinal Tract Adenocarcino |
| GILD | Nivolumab | Advanced Upper Gastrointestinal Tract Adenocarcino |
| GILD | Axicabtagene Ciloleucel | Relapsed or Refractory Large B-cell Lymphoma |
Phase 2 oncology (cancer) programs (327)
| Ticker | Drug | Indication |
|---|---|---|
| ACHV | Abiraterone Acetate | Prostate Cancer |
| ACHV | OGX-427 | Bladder Cancer |
| ACHV | Carboplatin | Squamous Cell Lung Cancer |
| ACHV | Apatorsen (OGX-427) | Squamous Cell Lung Cancer |
| ACHV | Gemcitabine | Squamous Cell Lung Cancer |
| ACHV | OGX-427 600 mg | Urologic Neoplasms |
| ACHV | OGX-427 1000 mg | Urologic Neoplasms |
| ACHV | Cisplatin | Urologic Neoplasms |
| ACHV | custirsen (OGX-011)/docetaxel | Prostate Cancer |
| ACHV | custirsen (OGX-011)/mitoxantrone | Prostate Cancer |
| ACHV | S-8184 Paclitaxel Injectable Emulsion | Ovarian Cancer |
| ACHV | TOCOSOL(R) Paclitaxel | Breast Cancer |
| ACHV | Experimental Arm: TOCOSOL Paclitaxel | Urologic Neoplasms |
| ACRV | ACR-368 | Head and Neck Squamous Cell Carcinoma |
| ACRV | Gemcitabine | Head and Neck Squamous Cell Carcinoma |
| ADCT | Loncastuximab Tesirine | B-cell Non Hodgkin Lymphoma |
| ADCT | Etoposide | B-cell Non Hodgkin Lymphoma |
| ADCT | Prednisone | Double-Expressor Lymphoma |
| ADCT | Vincristine | Double-Expressor Lymphoma |
| ADCT | Doxorubicin | Double-Expressor Lymphoma |
| ADCT | Cyclophosphamide | Double-Expressor Lymphoma |
| ADCT | Dexamethasone | B-cell Non Hodgkin Lymphoma |
| ADCT | ADCT-301 | Acute Myeloid Leukemia (AML) |
| ADCT | Epcoritamab | Large B-cell Lymphoma |
| ADCT | CAR T-cells (TBC) | B-cell Non Hodgkin Lymphoma |
| ADCT | Ifosfamide | B-cell Non Hodgkin Lymphoma |
| ADCT | Etoposide Phosphate | B-cell Non Hodgkin Lymphoma |
| ADCT | Carboplatin | B-cell Non Hodgkin Lymphoma |
| ADCT | Odronextamab | B-cell Non Hodgkin Lymphoma |
| ADCT | Loncastuximab tesirine 150 µg/Kg | Marginal Zone Lymphoma |
| ADCT | Loncastuximab tesirine 75µg/Kg | Marginal Zone Lymphoma |
| ADCT | Idelalisib | Relapsed Follicular Lymphoma |
| AGIO | AG-120 | Chondrosarcoma |
| AGIO | ivosidenib and nivolumab | Advanced Solid Tumor |
| AIM | Rintatolimod | Prostate Adenocarcinoma |
| AIM | Recombinant Interferon Alfa-2b | Prostate Adenocarcinoma |
| AIM | EC Aspirin | Prostate Adenocarcinoma |
| AIM | Pembrolizumab | Ovarian Cancer |
| AIM | Cisplatin | Ovarian Cancer |
| AIM | Celecoxib | Ovarian Cancer |
Phase 1 oncology (cancer) programs (314)
| Ticker | Drug | Indication |
|---|---|---|
| ACHV | Custirsen, paclitaxel and carboplatin | Cancer |
| ACHV | SN2310 Injectable Emulsion | Breast Neoplasms |
| ACRV | ACR-2316 | Specific Advanced Solid Tumors |
| ADCT | Camidanlumab Tesirine | Hodgkin Lymphoma |
| ADCT | Loncastuximab tesirine and rituximab (Lo | Central Nervous System Lymphoma |
| ADCT | Mosunetuzumab | B-Cell Non-Hodgkin Lymphoma |
| ADCT | Glofitamab | B-Cell Non-Hodgkin Lymphoma |
| ADCT | Polatuzumab Vedotin | B-Cell Non-Hodgkin Lymphoma |
| ADCT | Obinutuzumab | B-Cell Non-Hodgkin Lymphoma |
| ADCT | Loncastuximab Tesirine and Acalabrutinib | Chronic Lymphocytic Leukemia |
| ADCT | ADCT-901 | Advanced Solid Tumors |
| ADCT | ADCT-601 | Advanced Solid Tumors |
| ADCT | imvotamab | Non-Hodgkin Lymphoma |
| ADCT | Pembrolizumab | Head and Neck Cancer Squamous Cell Carcinoma |
| ADCT | Ibrutinib | Diffuse Large B-Cell Lymphoma |
| ADCT | Melphalan | Recurrent Diffuse Large B-Cell Lymphoma |
| ADCT | Carmustine | Recurrent Diffuse Large B-Cell Lymphoma |
| ADCT | Cytarabine | Recurrent Diffuse Large B-Cell Lymphoma |
| ADCT | Loncastuximab Tesirine and Durvalumab | Diffuse Large B-Cell Lymphoma |
| ADCT | ADCT-402 | Acute Lymphoblastic Leukemia |
| ADCT | ADCT-502 | Breast Cancer |
| AGIO | Ivosidenib | IDH1 Mutation Myeloid Neoplasms |
| AGIO | Enasidenib | Hematologic Neoplasms |
| AGIO | AG-636 | Lymphoma |
| AIM | Cisplatin + celecoxib + DC vaccine | Cancer of Ovary |
| AIM | Cisplatin + CKM + Celecoxib + DC Vaccine | Cancer of Ovary |
| AIM | Durvalumab | Metastatic Pancreatic Cancer |
| AIM | Chemokin Modulatory Regimen (5 MU/m2) | Colorectal Cancer |
| AIM | Chemokin Modulatory Regimen (20 MU/m2) | Colorectal Cancer |
| AIM | Chemokin Modulatory Regimen (10 MU/m2) | Colorectal Cancer |
| APGE | Opaganib | Multiple Myeloma |
| APGE | sphingosine kinase-2 inhibitor ABC294640 | Pancreatic Cancer |
| ARTV | AB-201 | Breast Cancer |
| ARTV | Bendamustine | Non Hodgkin Lymphoma |
| ARTV | GCC2005 | Lymphoma, T-Cell |
| ARVN | Samuraciclib | Breast Cancer |
| ARVN | Abiraterone | Prostate Cancer Metastatic |
| ARVN | Bavdegalutamide | Prostate Cancer Metastatic |
| ARVN | ARV-471 in combination with palbociclib | Breast Cancer |
| ARVN | Ribociclib | Breast Cancer |
Track cancer catalysts before they hit
BioRadar scores every upcoming FDA decision with an AI Probability of Approval, tracks cash runway and dilution risk, and sends free email alerts. Build a cancer watchlist in minutes.
Start free →
Data: ClinicalTrials.gov, SEC & FDA filings • Informational only, not investment advice. • All biotech stocks A–Z →